Industry News

France’s National Research Agency awards funding to OPTIVAC project

Centerwatch - Mon, 2014-10-27 08:53
Imaxio, a French biopharmaceutical company specialized in vaccines, has been awarded funding of $772,000 by the French National Research Agency (Agence Nationale de la Recherche, ANR) for the OPTIVAC project “leveraging On t-cell immune resPonse To Improve influenza VACcines.”
Categories: Industry News

Finding Opportunities in the Information Value Chain

Centerwatch - Mon, 2014-10-27 03:00
At a recent meeting with a molecular diagnostics client, I went around the room and asked each executive to tell me what business he/she was in.
Categories: Industry News

Esomeprazole Plus Alginate vs. Esomeprazole Alone for Treatment of Nighttime Reflux Symptom and Sleep Disturbances

sleep - Sun, 2014-10-26 20:00
Status: Not yet recruiting, Condition Summary: Gastroesophageal Reflux Disease; Heartburn; Sleep Disturbance
Categories: Industry News

Newly Added Guidance Documents

FDA News - Fri, 2014-10-24 10:25
Categories: Industry News

Lilly, Zymeworks expand collaboration agreement

Centerwatch - Fri, 2014-10-24 09:10
Eli Lilly and Zymeworks, a Vancouver-based, privately held biotherapeutics company, are expanding an existing licensing and collaboration agreement. Originally announced in January, the global strategic collaboration is focused on the development of an undisclosed number of novel bi-specific antibody therapeutics using Zymeworks' proprietary Azymetric platform.
Categories: Industry News

Celgene collaborates with Sutro Biopharma, inks option to acquire

Centerwatch - Fri, 2014-10-24 09:09
Sutro Biopharma, located in South San Francisco, has entered into a strategic collaboration and option agreement with Celgene to discover and develop multispecific antibodies and antibody drug conjugates (ADCs). This new agreement follows the December 2012 collaboration between the two companies and focuses on the field of immuno-oncology, while further broadening the Sutro platform for discovery, development and manufacture of best-in-class biotherapeutics.
Categories: Industry News

J&J Innovation adds J-Labs incubator at Texas Medical Center

Centerwatch - Fri, 2014-10-24 09:07
Johnson & Johnson Innovation plans to expand J-Labs (formerly Janssen Labs) to include a new incubator located within Texas Medical Center's new Innovation Institute. The 30,000-square-foot J-Labs facility will accommodate up to 50 life science startups.
Categories: Industry News

Xiaflex approved for concurrent treatment in Dupuytren's contracture patients

Centerwatch - Fri, 2014-10-24 08:48
Auxilium Pharmaceuticals has announced that the FDA has approved a supplemental Biologics Application (sBLA) for Xiaflex (collagenase clostridium histolyticum or CCH) for the treatment of up to two Dupuytren's contracture (DC) joints in the same hand during a single treatment visit.
Categories: Industry News

Measuring Sleep Disturbance Among Cancer Patients

sleep - Thu, 2014-10-23 20:00
Status: Active, not recruiting, Condition Summary: Advanced Cancer
Categories: Industry News

Treasury’s tax inversion changes scuttle some big biopharma mergers, modify others, prompting calls for Congressional corporate tax reform

Centerwatch - Thu, 2014-10-23 11:50
The widely-discussed $54.6 billion acquisition of Dublin-based Shire by AbbVie is officially canceled, having crumbled after a notice by the U.S. Treasury Department to tighten tax rules that deter U.S. companies from moving their legal headquarters to countries with lower business taxes.
Categories: Industry News

Cubist Pharmaceuticals names Robert J. Perez CEO

Centerwatch - Thu, 2014-10-23 11:47
Cubist Pharmaceuticals has selected Robert J. Perez as the company's CEO, effective January, 2015. Perez, who currently is Cubist's president and chief operating officer, will succeed Michael W. Bonney who is retiring from his current role as CEO on Dec. 31, and will become non-executive chair of Cubist's board of directors. Current board chair Kenneth M. Bate will become lead independent director.
Categories: Industry News

TWi Biotechnology receives Orphan Drug designation for AC-201

Centerwatch - Thu, 2014-10-23 11:29
TWi Biotechnology has received the designation of Orphan Drug from the FDA for using AC-201 to treat epidermolysis bullosa (EB). TWi Biotechnology has developed proprietary formulations to be used topically for the indication of EB.
Categories: Industry News

ProNAi Therapeutics adds five to senior management team

Centerwatch - Thu, 2014-10-23 11:17
ProNAi Therapeutics, a private company dedicated to developing and commercializing a new class of therapies based on its proprietary DNAi platform, has added five seasoned executives to its senior management team.
Categories: Industry News

Adheris Health, Behavioral Insights Group launch ethnographic study

Centerwatch - Thu, 2014-10-23 09:51
Adheris Health, an inVentiv Health company and a provider of medication adherence programs, has announced the start of the next phase of an ethnographic study into how Americans make healthcare decisions and the role of American culture in influencing health behaviors.
Categories: Industry News

aTyr Pharma appoints John C. McKew vice president, research

Centerwatch - Thu, 2014-10-23 09:45
aTyr Pharma, an innovative rare disease therapeutics enterprise, has announced that John C. McKew, Ph.D., has joined the company as vice president, research. McKew brings more than two decades of experience in translational research, including key leadership positions at the NIH, Wyeth Research and Genetics Institute (prior to its acquisition by Wyeth). McKew will lead aTyr's efforts to expand and translate its novel Physiocrine biology into meaningful therapeutics to treat rare, grave immune-driven disorders.
Categories: Industry News

Roche invests in its Switzerland site

Centerwatch - Thu, 2014-10-23 09:23
Roche has presented development plans for its Basel, Switzerland site. Over the next 10 years, Roche will invest $3.1 billion in the construction of a new R&D center for around 1,900 employees, a state-of-the-art office building for up to 1,700 employees.
Categories: Industry News

Center for Connected Health, Daiichi Sankyo ink mobile app agreement

Centerwatch - Thu, 2014-10-23 09:19
The Center for Connected Health, a division of Partners HealthCare, a Boston-based healthcare delivery system founded by Harvard Medical School affiliated teaching institutions Brigham and Women's Hospital and Massachusetts General Hospital, has announced a co-development agreement with Japanese pharmaceutical Daiichi Sankyo to create a mobile app to serve as a coaching platform for patients with atrial fibrillation who have been prescribed oral anticoagulation therapy.
Categories: Industry News

European Union to boost Ebola research with $30.9 million

Centerwatch - Thu, 2014-10-23 09:17
The European Commission (E.C.) has announced $30.9 million from the European Union (E.U.) budget for urgently needed Ebola research. The funding will go to five projects, ranging from a large-scale clinical trial of a potential vaccine, to testing existing and novel compounds to treat Ebola. The money from Horizon 2020, an E.U. research and innovation program, will be provided via a fast-track procedure in order to start work as soon as possible. The commission also is working with industry on the further development of vaccines, drugs and diagnostics for Ebola and other haemorrhagic diseases within the Innovative Medicines Initiative.
Categories: Industry News

Veeva Vault selected by inVentiv Health Clinical

Centerwatch - Thu, 2014-10-23 09:15
inVentiv Health Clinical, a Princeton, N.J.-based global supplier of drug development services, will replace its electronic trial master file (eTMF) content management system with California-based Veeva Systems’s Veeva Vault eTMF.
Categories: Industry News

ALS ACT, ALS Association, Northeast ALS Consortium request proposals

Centerwatch - Thu, 2014-10-23 09:12
ALS ACT, a novel academic-foundation-industry partnership; the ALS Association, a Wash. D.C.-based national nonprofit organization; and the translational Northeast ALS Consortium (NEALS) clinical trials network have announced a call for phase II clinical trial applications for novel, high-potential treatments in amyotrophic lateral sclerosis (ALS).
Categories: Industry News
Syndicate content